183 related articles for article (PubMed ID: 31920193)
21. Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction.
Ribed A; Romero-Jiménez RM; Escudero-Vilaplana V; Iglesias-Peinado I; Herranz-Alonso A; Codina C; Sanjurjo-Sáez M
Int J Clin Pharm; 2016 Apr; 38(2):280-8. PubMed ID: 26715547
[TBL] [Abstract][Full Text] [Related]
22. [Patient's beliefs about oral targeted therapies and impact on drug adherence in lung cancer: A pilot prospective study].
Torrecillas S; Perrot E; Gérinière L; Locatelli-Sanchez M; Laffay L; Souquet PJ; Couraud S
Rev Pneumol Clin; 2016 Feb; 72(1):25-34. PubMed ID: 26210879
[TBL] [Abstract][Full Text] [Related]
23. Oral agents for cancer: safety challenges and recommendations.
Rudnitzki T; McMahon D
Clin J Oncol Nurs; 2015 Jun; 19(3 Suppl):41-6. PubMed ID: 26030392
[TBL] [Abstract][Full Text] [Related]
24. Medication adherence to oral anticancer drugs: systematic review.
Huang WC; Chen CY; Lin SJ; Chang CS
Expert Rev Anticancer Ther; 2016; 16(4):423-32. PubMed ID: 26935964
[TBL] [Abstract][Full Text] [Related]
25. A randomized controlled trial of the feasibility and preliminary efficacy of a texting intervention on medication adherence in adults prescribed oral anti-cancer agents: study protocol.
Spoelstra SL; Given CW; Sikorskii A; Coursaris CK; Majumder A; DeKoekkoek T; Schueller M; Given BA
J Adv Nurs; 2015 Dec; 71(12):2965-76. PubMed ID: 26100719
[TBL] [Abstract][Full Text] [Related]
26. [Antineoplastic oral agents and drug-nutrient interactions: a sistematic review].
Jiménez Torres NV; Romero Crespo I; Ballester Solaz M; Albert Marí A; Jiménez Arenas V
Nutr Hosp; 2009; 24(3):260-72. PubMed ID: 19721898
[TBL] [Abstract][Full Text] [Related]
27. Overview of the challenges related to oral agents for cancer and their impact on adherence.
Tipton JM
Clin J Oncol Nurs; 2015 Jun; 19(3 Suppl):37-40. PubMed ID: 26030391
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
Carneiro BA; Kaplan JB; Giles FJ
Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
[TBL] [Abstract][Full Text] [Related]
29. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
30. Adherence and patients' experiences with the use of oral anticancer agents.
Timmers L; Boons CC; Kropff F; van de Ven PM; Swart EL; Smit EF; Zweegman S; Kroep JR; Timmer-Bonte JN; Boven E; Hugtenburg JG
Acta Oncol; 2014 Feb; 53(2):259-67. PubMed ID: 24266637
[TBL] [Abstract][Full Text] [Related]
31. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
Gater A; Heron L; Abetz-Webb L; Coombs J; Simmons J; Guilhot F; Rea D
Leuk Res; 2012 Jul; 36(7):817-25. PubMed ID: 22364811
[TBL] [Abstract][Full Text] [Related]
32. Challenges of Caregivers of Cancer Patients who are on Oral Oncolytic Therapy.
Marshall VK; Cairns PL
Semin Oncol Nurs; 2019 Aug; 35(4):363-369. PubMed ID: 31229341
[TBL] [Abstract][Full Text] [Related]
33. Assessing the need for improved strategies and medication-related education to increase adherence for oral anticancer medications in the young adult oncology population.
Divakaruni A; Saylor E; Duffy AP
J Oncol Pharm Pract; 2018 Jul; 24(5):337-342. PubMed ID: 28387636
[TBL] [Abstract][Full Text] [Related]
34. Interactions between oral antineoplastic agents and concomitant medication: a systematic review.
Carcelero E; Anglada H; Tuset M; Creus N
Expert Opin Drug Saf; 2013 May; 12(3):403-20. PubMed ID: 23586848
[TBL] [Abstract][Full Text] [Related]
35. Disparities and challenges in adherence to oral antineoplastic agents.
Accordino MK; Hershman DL
Am Soc Clin Oncol Educ Book; 2013; ():271-6. PubMed ID: 23714520
[TBL] [Abstract][Full Text] [Related]
36. Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs).
Di Minno A; Spadarella G; Tufano A; Prisco D; Di Minno G
Thromb Res; 2014 May; 133(5):699-704. PubMed ID: 24525314
[TBL] [Abstract][Full Text] [Related]
37. [Interaction of oral form anticancer drugs with grapefruit juice].
Cholewka-Stafińska M; Polaniak R; Kardas M; Grajek M; Grochowska-Niedworok E
Pol Merkur Lekarski; 2017 Jan; 42(247):30-33. PubMed ID: 28134229
[TBL] [Abstract][Full Text] [Related]
38. The Association Between Patient-Reported and Objective Oral Anticancer Medication Adherence Measures: A Systematic Review
.
Atkinson TM; Rodríguez VM; Gordon M; Avildsen IK; Emanu JC; Jewell ST; Anselmi KA; Ginex PK
Oncol Nurs Forum; 2016 Sep; 43(5):576-82. PubMed ID: 27541550
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?
Aghel N; Delgado DH; Lipton JH
Leukemia; 2018 Oct; 32(10):2095-2104. PubMed ID: 30201984
[TBL] [Abstract][Full Text] [Related]
40. Outcome Assessments and Cost Avoidance of an Oral Chemotherapy Management Clinic.
Wong SF; Bounthavong M; Nguyen CP; Chen T
J Natl Compr Canc Netw; 2016 Mar; 14(3):279-85. PubMed ID: 26957614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
